European healthcare M&A will stay in good shape in 2024 as the valuation gap narrows and lower multiples trigger opportunistic moves, dealmakers told Mergermarket. The biggest challenge for healthcare M&A in 2023 was the valuation gap between buyers and sellers, said Arvin Abraham, a Private Equity partner, to Mergermarket. However, more private equity (PE)-related transactions will reach the finish line from 1H24, as vendors wake up from dreams of previously unachievable multiples, he said. Despite buoyant deal volumes, there is still something of a hangover from 2021, which saw exuberant valuations and deals happening at a phenomenal pace after the COVID-19 pandemic put the spotlight on the importance of healthcare and life sciences, Abraham agreed.